Epoetin Alfa

CHEMBL1201565 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

848.0 g/mol

LogP

0.8

Phase

4

This medication mimics the natural hormone erythropoietin to stimulate the bone marrow to produce more red blood cells. It is used to treat anemia caused by chronic kidney disease, chemotherapy, or certain other conditions.

Berat Molekul

848,0000 g/mol

LogP

0,80

TPSA

236,00 Å²

Lipinski RO5

Gagal

Area Terapeutik

Infectious Disease Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Bipolar Disorder Generalized Anxiety Disorder Multiple Sclerosis Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Lymphoma Nephrology Type 2 Diabetes Hypertension Breast Cancer Malaria HIV/AIDS Hepatitis C Heart Failure Cardiovascular Disease Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CCO)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O

InChI

InChI=1S/C42H73NO16/c1-22-18-27(16-17-44)36(59-40-34(47)33(43(8)9)35(24(3)56-40)58-32-21-42(7,51)39(49)26(5)55-32)37(52-10)28(45)19-30(46)53-23(2)14-12-11-13-15-29(22)57-31-20-41(6,50)38(48)25(4)54-31/h11-13,15,22-29,31-40,44-45,47-51H,14,16-21H2,1-10H3/b12-11+,15-13+/t22-,23-,24-,25+,26+,27+,28-,29+,31+,32+,33-,34-,35-,36+,37+,38+,39+,40+,41-,42-/m1/s1

Molecular Formula

C42H73NO16

HBD / HBA

7 / 17

Ikatan yang Dapat Dirotasi

10

Atom Berat

59

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This medication mimics the natural hormone erythropoietin to stimulate the bone marrow to produce more red blood cells. It is used to treat anemia caused by chronic kidney disease, chemotherapy, or certain other conditions.

Yes, Epoetin Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201565. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 92043599. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Epoetin Alfa di PillFYI

Struktur

Data Cepat

Rumus: C42H73NO16
Sinonim: 2

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.